Sino Biological

Executive Summary

Sino Biological is a leading global supplier of recombinant antibodies, proteins, and proteomics research tools, as well as a contract research organization (CRO). Founded in 2007 and headquartered in Beijing, China, the company serves pharmaceutical and academic researchers in infectious disease, oncology, and neuroscience. With a catalog of over 50,000 products and a reputation for high quality and reliability, Sino Biological has become a critical partner in the life science research community. The company's platform business model generates recurring revenue from product sales and service contracts, providing stable cash flows. Its public listing and large employee base (1,000+) reflect a mature operation. However, as a supplier, its growth is tied to the overall R&D spending in pharma and biotech, which faces headwinds from funding volatility. Nonetheless, Sino Biological's strong market position and expansion into new areas offer upside potential.

Upcoming Catalysts (preview)

• Q3 2026Launch of expanded recombinant protein catalog for emerging targets70% success
• Q3 2026New CRO service contract with top-tier pharmaceutical company60% success
• Q3 2026Expansion into neuroscience research tools market65% success